Experimental haemorrhagic effect of two-domain non-glycosylated tissue factor pathway inhibitor compared to low molecular weight heparin
(1996) In Thrombosis and Haemostasis 75(4). p.585-589- Abstract
The glycosylated multivalent three-domain Kunitz inhibitor TFPI is a natural inhibitor of tissue factor-FVIIa complex in the presence of FXa. TFPI has an experimental antithrombotic capacity indistinguishable from LMWH in a prophylactic dose, regardless of glycosylation and of the third domain. An inherited equilibrium between antithrombosis and haemorrhage exists. The aim of the study was to evaluate whether a two-domain non-glycosylated TFPI (117QTFPI1-161) has a bleeding potential in a rat gastric mucosa model. Groups; placebo, LMWH (tinzaparin) 60 and 250 anti-Xa IU/kg and 117QTFPI1-161 1.0 and 10.0 mg/kg, given i.v. (bolus injection), randomised double dummy design. All actively treated groups significantly... (More)
The glycosylated multivalent three-domain Kunitz inhibitor TFPI is a natural inhibitor of tissue factor-FVIIa complex in the presence of FXa. TFPI has an experimental antithrombotic capacity indistinguishable from LMWH in a prophylactic dose, regardless of glycosylation and of the third domain. An inherited equilibrium between antithrombosis and haemorrhage exists. The aim of the study was to evaluate whether a two-domain non-glycosylated TFPI (117QTFPI1-161) has a bleeding potential in a rat gastric mucosa model. Groups; placebo, LMWH (tinzaparin) 60 and 250 anti-Xa IU/kg and 117QTFPI1-161 1.0 and 10.0 mg/kg, given i.v. (bolus injection), randomised double dummy design. All actively treated groups significantly prolonged both the bleeding volume (493-984 μl) and the bleeding time (10-20 min) compared to placebo (41 μl, 2 min). It was not possible to distinguish a difference between the lower dose of LMWH and 117QTFPI1-161 in either parameter (p = 0.23-0.71). The two doses of 117QTFPI1-161 caused elevation of plasma-TFPI, 18 and 150 times baseline value. Both LMWH doses (0.6-3.2 anti-Xa IU/ml) and both 117QTFPI1-161 doses (0.2-2.7 anti-Xa IU/ml), caused significant effect in the anti-Xa assay, however 117QTFPI1-161 significantly less. Only the largest dose of 117QTFPI1-161 caused significant prolongation in the APTT assay (34 s). Both doses of LMWH caused significant prolongation (60-300 s). LMWH was the only substance to prolong the dilute-PT assay. Non-glycosylated two-domain 1.0 mg/kg TFPI, yielding supra physiological plasma concentration, has an experimental haemorrhagic potential indistinguishable from LMWH in a prophylactic dose. The effect mediated by this type of TFPI could primarily be due to an inhibition of FXa.
(Less)
- author
- Holst, Jan LU ; Lindblad, Bengt LU ; Matthíasson, Stefan E. ; Stjernquist, Ulf ; Ezban, Mirella ; Østergaard, Per B. and Hedner, Ulla LU
- publishing date
- 1996-04
- type
- Contribution to journal
- publication status
- published
- in
- Thrombosis and Haemostasis
- volume
- 75
- issue
- 4
- pages
- 585 - 589
- publisher
- Schattauer GmbH
- external identifiers
-
- scopus:0029997618
- pmid:8743183
- ISSN
- 0340-6245
- language
- English
- LU publication?
- no
- id
- d1688f7d-83de-463f-a618-f95f068afde6
- date added to LUP
- 2018-03-23 16:06:32
- date last changed
- 2024-01-14 17:27:07
@article{d1688f7d-83de-463f-a618-f95f068afde6, abstract = {{<p>The glycosylated multivalent three-domain Kunitz inhibitor TFPI is a natural inhibitor of tissue factor-FVIIa complex in the presence of FXa. TFPI has an experimental antithrombotic capacity indistinguishable from LMWH in a prophylactic dose, regardless of glycosylation and of the third domain. An inherited equilibrium between antithrombosis and haemorrhage exists. The aim of the study was to evaluate whether a two-domain non-glycosylated TFPI (117QTFPI<sub>1-161</sub>) has a bleeding potential in a rat gastric mucosa model. Groups; placebo, LMWH (tinzaparin) 60 and 250 anti-Xa IU/kg and 117QTFPI<sub>1-161</sub> 1.0 and 10.0 mg/kg, given i.v. (bolus injection), randomised double dummy design. All actively treated groups significantly prolonged both the bleeding volume (493-984 μl) and the bleeding time (10-20 min) compared to placebo (41 μl, 2 min). It was not possible to distinguish a difference between the lower dose of LMWH and 117QTFPI<sub>1-161</sub> in either parameter (p = 0.23-0.71). The two doses of 117QTFPI<sub>1-161</sub> caused elevation of plasma-TFPI, 18 and 150 times baseline value. Both LMWH doses (0.6-3.2 anti-Xa IU/ml) and both 117QTFPI<sub>1-161</sub> doses (0.2-2.7 anti-Xa IU/ml), caused significant effect in the anti-Xa assay, however 117QTFPI<sub>1-161</sub> significantly less. Only the largest dose of 117QTFPI<sub>1-161</sub> caused significant prolongation in the APTT assay (34 s). Both doses of LMWH caused significant prolongation (60-300 s). LMWH was the only substance to prolong the dilute-PT assay. Non-glycosylated two-domain 1.0 mg/kg TFPI, yielding supra physiological plasma concentration, has an experimental haemorrhagic potential indistinguishable from LMWH in a prophylactic dose. The effect mediated by this type of TFPI could primarily be due to an inhibition of FXa.</p>}}, author = {{Holst, Jan and Lindblad, Bengt and Matthíasson, Stefan E. and Stjernquist, Ulf and Ezban, Mirella and Østergaard, Per B. and Hedner, Ulla}}, issn = {{0340-6245}}, language = {{eng}}, number = {{4}}, pages = {{585--589}}, publisher = {{Schattauer GmbH}}, series = {{Thrombosis and Haemostasis}}, title = {{Experimental haemorrhagic effect of two-domain non-glycosylated tissue factor pathway inhibitor compared to low molecular weight heparin}}, volume = {{75}}, year = {{1996}}, }